Subscribe To
Sutro: too little, too late for stro-002, but platform is interesting
STRO is playing second fiddle to perpetually second fiddle player ImmunoGen in ovarian cancer. Although...
April 11, 2023, 1:17 pm
Astrazeneca premium justified by long-term potential says broker
Encouraging Phase III DUO-O trial results from a new combination of AstraZeneca's Imfinzi and Lynparza drugs plus Avastin in advanced ...
April 6, 2023, 7:20 am
Astrazeneca's (azn) drug combo meets ovarian cancer study goal
Interim data from a late-stage study shows that AstraZeneca's (AZN) cancer drugs, Lynparza and Imfinzi improved progression-free survival in certain p...
April 5, 2023, 1:42 pm
Medical behemoth astrazeneca flirts with breakout on fresh hope in ovarian cancer
AstraZeneca said Wednesday a combination of its drugs Lynparza and Imfinzi met the goal of a key study, leading AZN stock to surge. The post Medical B...
April 5, 2023, 10:20 am
Astrazeneca drug combo improves ovarian cancer survival rate
AstraZeneca PLC (LSE:AZN), the Anglo-Swedish pharmaceutical giant, has announced encouraging results from a planned interim analysis of its DUO-O phas...
April 5, 2023, 3:07 am
Sutro biopharma reports full year 2022 financial results, business highlights and select anticipated milestones
– Sutro plans to initiate a Phase 2/3 registration-directed study of luvelta for patients with platinum resistant ...
March 30, 2023, 8:30 pm
Allarity's stock falls after saying enrollment in two clinical trials is slow
Shares of Allarity Therapeutics Inc. ALLR, -4.51% plunged 17% in premarket trading on Tuesday after the company told investors that it's struggled to ...
March 28, 2023, 8:34 am
Imunon to hold fourth quarter 2022 financial results and business update conference call on thursday, march 30, 2023
LAWRENCEVILLE, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing ...
March 23, 2023, 8:30 am
Celcuity to present preclinical data on therapeutic effects of gedatolisib in gynecological cancer models at aacr annual meeting 2023
MINNEAPOLIS, MN / ACCESSWIRE / March 15, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted...
March 15, 2023, 7:35 pm
Genetic testing market size to hit usd 17.48 billion by 2030 at 10.10% cagr – report by market research future (mrfr)
Genetic Testing Market Size and Trends Analysis By Type (Prescribed Genetic Testing and Direct-to-Consumer Genetic Testing), Method (Molecular Genetic...
February 27, 2023, 2:45 pm
Tcr² therapeutics: refocused pipeline puts it on a solid path
Reprioritization of pipeline sees 40% reduction of workforce with enough cash to fund pipeline into early 2025. Proof of concept established using gav...
February 15, 2023, 6:00 am
Update – oncoc4 announces first patient dosed in preserve-004, a phase 2 clinical trial of onc-392 in combination with keytruda® (pembrolizumab) in patients with platinum-resistant ovarian cancer
The Phase 2 multicenter, open-label combination trial builds upon the promising results of monotherapeutic activity of ONC-392 seen in previous clinic...
December 30, 2022, 3:43 pm
Aravive: down but not out with pivotal ovarian data due in 2023
Aravive shareholders have been heavily diluted and suffered substantial losses in 2022. The company has struggled for cash, but now says it has funds ...
December 14, 2022, 8:45 am
Clovis enters bankruptcy with deal to sell cancer-drug candidate to novartis
Clovis Oncology, maker of ovarian cancer drug Rubraca, has filed for chapter 11 and proposed selling a ...
December 12, 2022, 2:05 pm
Biovaxys technology successfully tests production of ovarian cancer vaccine using a patient's ovarian tumor
BioVaxys Technology Corp has successfully completed a sterile and bacteria-free test-run production of its ova...
December 1, 2022, 10:02 am
Immunogen: elucidating ramifications of the elahere approval
ImmunoGen recently gained the accelerated approval of mirvetuximab (Elahere) for resistant ovarian canc...
November 24, 2022, 3:15 am
Gsk second-line applications of new cancer drug will be restricted
GSK PLC (LSE:GSK, NYSE:GSK) said the second-line applications of its cancer drug will be limited in scope. The front-line use of Zejula, which has bee...
November 11, 2022, 2:28 am
Why vascular biogenics stock is plunging
Vascular Biogenics Ltd (NASDAQ: VBLT) shares are falling Wednesday after the company announced that the data from its Phase 3 OVAL trial of ofra-vec ...
July 20, 2022, 9:44 am
Why clovis oncology stock is taking a step backward today
A key label expansion for the company's ovarian cancer drug could take longer than expected....
July 7, 2022, 12:27 pm
Immunogen: possible accelerated fda approval for ovarian cancer treatment
PDUFA date with Priority Review for mirvetuximab for treatment of ovarian cancer patients with high fol...
June 20, 2022, 2:51 pm